A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

Brief description of study

This study is testing the effectiveness of a new drug, MRTX1719, in patients with advanced solid tumors that have a specific genetic change called MTAP deletion. The study follows guidelines from the U.S. Food and Drug Administration (FDA). The study starts with Phase 1, which will test different doses of MRTX1719 to find the most effective one with less side effects. In Phase 2, MRTX1719 will be tested in different groups of patients based on their type of cancer and other characteristics to see how well the drug works and how safe it is. There are plans to make changes during the study to prepare for future tests, depending on the results. The study includes careful monitoring, genetic testing to confirm eligibility, and regular checks on how the drug affects the patients.


Clinical Study Identifier: s24-00461
ClinicalTrials.gov Identifier: NCT05245500
Principal Investigator: Kristen Spencer.
Other Investigators: Nila Theresa De La Rosa, Elaine Shum, Scot Niglio, Kirby Rodriguez, Janice Mehnert, Maya Dimitrova, Eneil De La Pena, Jessica Wang, Monica Rivera, Danny Perlaza, Keriann M Scavone, Marissa Rybstein, Joshua K Sabari, Nina Beri, Paul E. Oberstein, David R. Wise, Elka R Travis, Salman Rafi Punekar, Jeffrey G Schneider, Zujun Li, Samantha VanMaanen, James Newman, Kathleen M Madden, Nancy Chan, Michael Shusterman, Alexander A Hindenburg, Ruth A White, Douglas K Marks.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.